Literature DB >> 16425132

The effect of bacille Calmette-Guérin vaccine strain and route of administration on induced immune responses in vaccinated infants.

Virginia Davids1, Willem A Hanekom, Nazma Mansoor, Hoyam Gamieldien, Sebastian J Gelderbloem, Anthony Hawkridge, Gregory D Hussey, E Jane Hughes, Jorge Soler, Rose Ann Murray, Stanley R Ress, Gilla Kaplan.   

Abstract

Vaccination with Mycobacterium bovis bacille Calmette-Guerin (BCG) has variable efficacy in preventing tuberculosis. Both BCG strain and route of administration have been implicated in determining efficacy; however, these variables are not considered in current clinical recommendations for vaccine choice. We evaluated antigen-specific immunity after percutaneous or intradermal administration of Japanese BCG or intradermal administration of Danish BCG. Ten weeks after vaccination of neonates, percutaneous Japanese BCG had induced significantly higher frequencies of BCG-specific interferon- gamma -producing CD4(+) and CD8(+) T cells in BCG-stimulated whole blood than did intradermal Danish BCG. Similarly, percutaneous vaccination with Japanese BCG resulted in significantly greater secretion of the T helper 1-type cytokines interferon- gamma, tumor necrosis factor- alpha , and interleukin-2; significantly lower secretion of the T helper 2-type cytokine interleukin-4; and greater CD4(+) and CD8(+) T cell proliferation. Thus, BCG strain and route of neonatal vaccination confer different levels of immune activation, which may affect the efficacy of the vaccine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16425132     DOI: 10.1086/499825

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  54 in total

1.  Commonly administered bacille Calmette-Guerin strains induce comparable immune response.

Authors:  Jun-Fang Wang; Fu-Ying Dai; Xue-Li Gong; Lang Bao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 2.  Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?

Authors:  Juan I Moliva; Joanne Turner; Jordi B Torrelles
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 3.641

3.  A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents.

Authors:  Chelsea Carpenter; John Sidney; Ravi Kolla; Kaustuv Nayak; Helena Tomiyama; Claudia Tomiyama; Oscar A Padilla; Virginie Rozot; Syed F Ahamed; Carlos Ponte; Valeria Rolla; Paulo R Antas; Anmol Chandele; John Kenneth; Seetha Laxmi; Edward Makgotlho; Valentina Vanini; Giuseppe Ippolito; Alexandra S Kazanova; Alexander V Panteleev; Willem Hanekom; Harriet Mayanja-Kizza; David Lewinsohn; Mayuko Saito; M Juliana McElrath; W Henry Boom; Delia Goletti; Robert Gilman; Irina V Lyadova; Thomas J Scriba; Esper G Kallas; Kaja Murali-Krishna; Alessandro Sette; Cecilia S Lindestam Arlehamn
Journal:  Tuberculosis (Edinb)       Date:  2015-08-01       Impact factor: 3.131

4.  Dose-dependent immune response to Mycobacterium bovis BCG vaccination in neonates.

Authors:  Virginia Davids; Willem Hanekom; Sebastian J Gelderbloem; Anthony Hawkridge; Gregory Hussey; Ronel Sheperd; Lesley Workman; Jorge Soler; Rose Ann Murray; Stanley R Ress; Gilla Kaplan
Journal:  Clin Vaccine Immunol       Date:  2006-12-20

5.  Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.

Authors:  Xindong Teng; Maopeng Tian; Jianrong Li; Songwei Tan; Xuefeng Yuan; Qi Yu; Yukai Jing; Zhiping Zhang; Tingting Yue; Lei Zhou; Xionglin Fan
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 6.  Tuberculosis vaccines in clinical trials.

Authors:  Rosalind Rowland; Helen McShane
Journal:  Expert Rev Vaccines       Date:  2011-05       Impact factor: 5.217

7.  BCG and Kawasaki disease in Mexico and Japan.

Authors:  Luisa Berenise Gamez-Gonzalez; Hiromichi Hamada; Beatriz Adriana Llamas-Guillen; Miguel Ruiz-Fernandez; Marco Yamazaki-Nakashimada
Journal:  Hum Vaccin Immunother       Date:  2017-03-10       Impact factor: 3.452

8.  The tuberculin skin test (TST) is affected by recent BCG vaccination but not by exposure to non-tuberculosis mycobacteria (NTM) during early life.

Authors:  Sarah Burl; Uche J Adetifa; Momodou Cox; Ebrima Touray; Hilton Whittle; Helen McShane; Sarah L Rowland-Jones; Katie L Flanagan
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

9.  A comprehensive survey of single nucleotide polymorphisms (SNPs) across Mycobacterium bovis strains and M. bovis BCG vaccine strains refines the genealogy and defines a minimal set of SNPs that separate virulent M. bovis strains and M. bovis BCG strains.

Authors:  M Carmen Garcia Pelayo; Swapna Uplekar; Andrew Keniry; Pablo Mendoza Lopez; Thierry Garnier; Javier Nunez Garcia; Laura Boschiroli; Xiangmei Zhou; Julian Parkhill; Noel Smith; R Glyn Hewinson; Stewart T Cole; Stephen V Gordon
Journal:  Infect Immun       Date:  2009-03-16       Impact factor: 3.441

10.  Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles.

Authors:  Andreia P Soares; Thomas J Scriba; Sarah Joseph; Ryhor Harbacheuski; Rose Ann Murray; Sebastian J Gelderbloem; Anthony Hawkridge; Gregory D Hussey; Holden Maecker; Gilla Kaplan; Willem A Hanekom
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.